Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
NCT06089369
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
360
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Sintilimab (9 cycles)
DRUG:
Sintilimab (18 cycles)
OTHER:
Active surveillance
Sponsor
Tongji Hospital